OpGen Inc (OPGN)-医療機器分野:企業M&A・提携分析

◆英語タイトル:OpGen Inc (OPGN) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8010943
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月21日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, swift detection and analysis of antibiotic resistance, and detection of pathogens in blood cultures. It is also developing Acuitas Lighthouse, an exhaustive database of various types of pathogens for providing rapid diagnostics, and healthcare management information. OpGen offers its surveillance products and customized screening services to healthcare providers to protect the hospital biome and optimize patient care. The company sells its products in the US and abroad. OpGen is headquartered in Gaithersburg, Maryland, the US.

OpGen Inc (OPGN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OpGen Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
OpGen Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
OpGen Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
OpGen Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
OpGen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
OpGen Inc, Medical Equipment, Deal Details 12
Venture Financing 12
AdvanDx Raises USD2.5 Million in Venture Financing 12
OpGen Raises USD1.2 Million in Venture Financing 13
Opgen Raises USD1 Million in Venture Financing 14
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 15
OpGen Raises US$2 Million In Venture Financing 16
AdvanDx Raises US$2 Million In Venture Financing 17
OpGen Raises Additional US$2.6 Million In Series C Financing 18
OpGen Secures An Additional US$3 Million In Series B Round Of Financing 20
Partnerships 22
OpGen Enters into Research Agreement with Merck 22
OpGen Enters into Co-Development Agreement with Fluidigm 23
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 24
OpGen Enters Into Co-Development Agreement With In-Q-Tel 25
Equity Offering 26
OpGen Plans to Raise Funds through Public Offering of Units 26
Opgen Raises USD10 Million in Public Offering of Units 27
OpGen to Raise upto USD11.5 Million in Public Offering of Shares 29
OpGen Raises USD10.4 Million in Private Placement of Shares and Warrants 30
OpGen Raises USD17 Million in IPO 32
Debt Offering 34
OpGen Raises USD0.5 Million in Debt Financing 34
OpGen Raises USD1.5 Million in Private Placement of 8% Notes 35
Acquisition 36
OpGen Acquires AdvanDx 36
OpGen Inc – Key Competitors 37
OpGen Inc – Key Employees 38
OpGen Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Nov 07, 2017: OpGen Reports 2017 Third Quarter Financial Results and Provides Business Update 40
Aug 08, 2017: OpGen Reports 2017 Second Quarter Financial Results and Provides Business Update 42
Apr 26, 2017: OpGen Announces 2017 First Quarter Financial Results 44
Mar 23, 2017: OpGen Announces 2016 Fourth Quarter and Year End Financial Results 45
Jan 26, 2017: OpGen Reports Preliminary Fourth Quarter and Full Year 2016 Financial Results 47
Oct 24, 2016: OpGen Reports 2016 Third Quarter Financial Results and Provides Business Update 49
Aug 09, 2016: OpGen Reports 2016 Second Quarter Financial Results and Provides Business Update 50
May 12, 2016: OpGen Reports 2016 First Quarter Financial Results and Business Update 51
Mar 30, 2016: OpGen Announces 2015 Fourth Quarter and Full Year Financial Results 52
Corporate Communications 53
Apr 27, 2017: OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors 53
May 02, 2016: OpGen Appoints Harry J. D’Andrea to Board of Directors 54
Mar 21, 2016: OpGen Announces New Members to its Clinical Advisory Board 55
Government and Public Interest 56
May 04, 2016: OpGen and District of Columbia Hospital Association Complete First Citywide Quantification of Multidrug-Resistant Organism (MDRO) Prevalence in Washington, D.C.-based Healthcare Facilities 56
Product News 57
Apr 12, 2017: OpGen to Present Antibiotic Resistance Prediction Data at 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 57
Feb 14, 2017: OpGen Presents Rapid Acuitas Genetic Test Data at Advances in Genome Biology and Technology Meeting 59
Oct 26, 2016: Opgen’s Infectious Disease Portfolio Highlighted At IDWeek 2016 60
Other Significant Developments 61
Jun 15, 2017: OpGen’s Acuitas Detection Technology Utilized in Publication Revealing Prevalence of CRE in Washington D.C. Healthcare Facilities 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
OpGen Inc, Medical Equipment, Key Facts, 2016 2
OpGen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
OpGen Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
OpGen Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
OpGen Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
OpGen Inc, Deals By Market, 2011 to YTD 2017 9
OpGen Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
AdvanDx Raises USD2.5 Million in Venture Financing 12
OpGen Raises USD1.2 Million in Venture Financing 13
Opgen Raises USD1 Million in Venture Financing 14
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 15
OpGen Raises US$2 Million In Venture Financing 16
AdvanDx Raises US$2 Million In Venture Financing 17
OpGen Raises Additional US$2.6 Million In Series C Financing 18
OpGen Secures An Additional US$3 Million In Series B Round Of Financing 20
OpGen Enters into Research Agreement with Merck 22
OpGen Enters into Co-Development Agreement with Fluidigm 23
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 24
OpGen Enters Into Co-Development Agreement With In-Q-Tel 25
OpGen Plans to Raise Funds through Public Offering of Units 26
Opgen Raises USD10 Million in Public Offering of Units 27
OpGen to Raise upto USD11.5 Million in Public Offering of Shares 29
OpGen Raises USD10.4 Million in Private Placement of Shares and Warrants 30
OpGen Raises USD17 Million in IPO 32
OpGen Raises USD0.5 Million in Debt Financing 34
OpGen Raises USD1.5 Million in Private Placement of 8% Notes 35
OpGen Acquires AdvanDx 36
OpGen Inc, Key Competitors 37
OpGen Inc, Key Employees 38
OpGen Inc, Subsidiaries 39

★海外企業調査レポート[OpGen Inc (OPGN)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dialog Group Bhd (DIALOG):企業の財務・戦略的SWOT分析
    Dialog Group Bhd (DIALOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Thai Packaging & Printing Public Company Limited:企業の戦略・SWOT・財務情報
    Thai Packaging & Printing Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Thai Packaging & Printing Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …
  • ANI Technologies Pvt Ltd:企業の戦略的SWOT分析
    ANI Technologies Pvt Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • AENZA SAA (AENZAC1):企業の財務・戦略的SWOT分析
    AENZA SAA (AENZAC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Vortex Energy Holding AG:電力:M&Aディール及び事業提携情報
    Summary Vortex Energy Holding AG (Vortex Energy) is a provider of renewable energy services. The company's services include development, consulting, financing, planning, implementation, construction, technical management, technical inspection, commercial management, and energy trading services. It a …
  • UGL Ltd:企業の戦略的SWOT分析
    UGL Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Harvard Stem Cell Institute-製薬・医療分野:企業M&A・提携分析
    Summary Harvard Stem Cell Institute (HSCI), a subsidiary of Harvard University is a healthcare institute that conducts research on advance stem cell science using stem cell biology to develop new treatments and cures for disease. The institute provides research programs such as disease programs, cor …
  • SNC-Lavalin Group Inc.:企業の戦略・SWOT・財務分析
    SNC-Lavalin Group Inc. - Strategy, SWOT and Corporate Finance Report Summary SNC-Lavalin Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • PT Tempo Scan Pacific Tbk (TSPC):企業の財務・戦略的SWOT分析
    PT Tempo Scan Pacific Tbk (TSPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Lonza Group Ltd (LONN)-製薬・医療分野:企業M&A・提携分析
    Summary Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B co …
  • John Menzies plc:企業の戦略・SWOT・財務情報
    John Menzies plc - Strategy, SWOT and Corporate Finance Report Summary John Menzies plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Theratechnologies Inc (TH):製薬・医療:M&Aディール及び事業提携情報
    Summary Theratechnologies Inc (Theratechnologies) is a pharmaceutical company that focuses on the discovery and development of drugs for metabolic disorders. The company develops therapeutic peptide products, with an emphasis on growth releasing factor (GRF) peptides. Its lead products include Egrif …
  • Cincinnati Bell Inc (CBB):企業の財務・戦略的SWOT分析
    Cincinnati Bell Inc (CBB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • SK E&S Co Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary SK E&S Co Ltd (SK E&S) a subsidiary of SK Holdings Co Ltd is a utility service provider that offers natural gas and electricity distribution. The company’s business activities include city gas, district energy, power, overseas business and LNG. It operates and supplies electricity from its L …
  • ISU ABXIS Co Ltd (086890):製薬・医療:M&Aディール及び事業提携情報
    Summary ISU ABXIS Co Ltd (ISU ABXIS), a subsidiary of ISU Chemical Co Ltd is a biotechnology company that discovers and develops diagnostic products and therapeutic antibodies. The company’s products include fabagal, abcertin, and clotinab. It offers clinical labs, in vitro diagnostics, chemotherapy …
  • KVK-Tech Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary KVK-Tech Inc (KVK-Tech) is a developer and manufacturer of generic pharmaceuticals. The company's products include benzphetamine HCL, betaxolol, chlorphen-12, cyclobenzaprine HCL, diethylpropion HCL, hydroxyzine HCL, indomethacin extended release, phentermine hydrochloride USP, phendimetrazi …
  • The 77 Bank Ltd:企業の戦略・SWOT・財務情報
    The 77 Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The 77 Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Faron Pharmaceuticals Oy (FARN):企業の財務・戦略的SWOT分析
    Summary Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that develops treatments for unmet medical needs. The company is developing pipeline products with a focus on vascular damage, acute organ traumas and cancer immunotherapy. It offers Clevegen, a humanized Clever-1 …
  • Infant Bacterial Therapeutics AB (IBT B):製薬・医療:M&Aディール及び事業提携情報
    Summary Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacil …
  • Pioneer Energy Services Corp (PES):企業の財務・戦略的SWOT分析
    Pioneer Energy Services Corp (PES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆